14,963 Shares in Nkarta, Inc. (NASDAQ:NKTX) Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. bought a new position in shares of Nkarta, Inc. (NASDAQ:NKTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,963 shares of the company’s stock, valued at approximately $37,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Erste Asset Management GmbH bought a new position in Nkarta during the third quarter worth $33,000. GAMMA Investing LLC increased its position in Nkarta by 110.9% during the third quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock worth $45,000 after acquiring an additional 5,243 shares during the period. Intech Investment Management LLC bought a new position in Nkarta during the third quarter worth $74,000. SG Americas Securities LLC bought a new position in Nkarta during the third quarter worth $93,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Nkarta by 92.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,710 shares of the company’s stock worth $122,000 after buying an additional 9,975 shares in the last quarter. Institutional investors own 80.54% of the company’s stock.

Nkarta Stock Performance

Shares of NASDAQ:NKTX opened at $2.26 on Wednesday. Nkarta, Inc. has a 52 week low of $2.08 and a 52 week high of $16.24. The company’s fifty day moving average is $2.46 and its 200-day moving average is $3.87. The company has a market capitalization of $159.49 million, a PE ratio of -1.20 and a beta of 0.85.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). On average, analysts forecast that Nkarta, Inc. will post -1.68 EPS for the current year.

Insider Activity at Nkarta

In related news, CEO Paul J. Hastings sold 17,378 shares of Nkarta stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the transaction, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 8.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on NKTX shares. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Mizuho decreased their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. HC Wainwright decreased their price target on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Rodman & Renshaw started coverage on shares of Nkarta in a research note on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target on the stock. Finally, Needham & Company LLC decreased their price target on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Nkarta currently has an average rating of “Buy” and a consensus price target of $15.00.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.